摘要
      细菌中的大肠杆菌素耐药性是公众健康的一大担忧，因为它是临床环境中治疗多药耐药性和碳青霉烯耐药性革兰氏阴性病原体传染病的最后手段。水产养殖和家禽环境中粘菌素耐药性的出现也增加了环境中与粘菌素抗性相关的风险。来自临床和非临床环境的关于细菌中粘菌素耐药性上升的报告数量惊人，令人不安。粘菌素耐药基因与其他抗生素耐药基因的共存给对抗抗生素耐药性带来了新的挑战。一些国家已经禁止生产、销售和分销用于食品生产动物的粘菌素及其制剂。然而，为了解决抗微生物耐药性问题，需要制定一项包括人类、动物和环境健康在内的单一健康方法倡议。在此，我们回顾了临床和非临床环境中细菌对粘菌素耐药性的最新报道，并审议了关于粘菌素耐药发展的新发现。本综述还讨论了全球在减轻粘菌素耐药性方面实施的举措及其优势和劣势。
Abstract
Colistin-resistance in bacteria is a big concern for public health, since it is a last resort antibiotic to treat infectious diseases of multidrug resistant and carbapenem resistant Gram-negative pathogens in clinical settings. The emergence of colistin resistance in aquaculture and poultry settings has escalated the risks associated with colistin resistance in environment as well. The staggering number of reports pertaining to the rise of colistin resistance in bacteria from clinical and non-clinical settings is disconcerting. The co-existence of colistin resistant genes with other antibiotic resistant genes introduces new challenges in combatting antimicrobial resistance. Some countries have banned the manufacture, sale and distribution of colistin and its formulations for food producing animals. However, to tackle the issue of antimicrobial resistance, a one health approach initiative, inclusive of human, animal, and environmental health needs to be developed. Herein, we review the recent reports in colistin resistance in bacteria of clinical and non-clinical settings, deliberating on the new findings obtained regarding the development of colistin resistance. This review also discusses the initiatives implemented globally in mitigating colistin resistance, their strength and weakness.

https://www.sciencedirect.com/science/article/abs/pii/S0944501323000174